目的 探討參芪降糖膠囊聯(lián)合格列本脲片治療2型糖尿病的臨床療效及安全性。方法 選取2013年1月-2014年6月來上海市徐匯區(qū)康健街道社區(qū)衛(wèi)生服務(wù)中心內(nèi)分泌科接受治療的2型糖尿病患者104例,隨機分為對照組(52例)和治療組(52例)。對照組患者給予口服格列本脲片,2.5 mg/次,3次/d,于餐前0.5 h口服;治療組在對照組基礎(chǔ)上加服參芪降糖膠囊,3粒/次,3次/d。兩組患者均治療8周。測定兩組患者治療前后的空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血紅蛋白(HbA1C)、血糖達標率、達標時間、中醫(yī)癥候積分,比較兩組的臨床療效和低血糖發(fā)生率。結(jié)果 治療后,兩組的FPG、2 h PG、HbA1C血糖指標較治療前均顯著下降,同組治療前后差異有統(tǒng)計學(xué)意義(P<0.05、0.01)。治療組經(jīng)治療后FPG、2 h PG、HbA1C下降更明顯,兩組比較差異具有顯著性(P<0.05、0.01)。治療后,與對照組比較,治療組患者血糖達標迅速且達標率高,血糖波動相對較小,低血糖發(fā)生率低,兩組比較差異有顯著性(P<0.05)。治療后,兩組的中醫(yī)臨床證候積分較治療前均明顯減少,差異具有統(tǒng)計學(xué)意義(P<0.05、0.01);治療后,治療組證候積分較對照組明顯降低,兩組比較差異有顯著性(P<0.05)。治療組總有效率94.23%,與對照組84.62%比較,差異具有統(tǒng)計學(xué)意義(P<0.05)。兩組患者治療期間均未見藥物相關(guān)的不良反應(yīng)。結(jié)論 參芪降糖膠囊聯(lián)合格列本脲片治療2型糖尿病在血糖控制、血糖達標率、達標時間、低血糖發(fā)生率方面優(yōu)于單用格列本脲片,臨床療效確切,未見嚴重不良反應(yīng),適合臨床推廣應(yīng)用。

Objective To study the efficacy and security of Shenqi Jiangtang Capsules combined with Glyburide Tablets in treatment of type 2 diabetes mellitus. Methods The patients with type 2 diabetes mellitus (104 cases) in Kangjian Community Health Service Center of Xuhui District from January 2013 to June 2014 were randomly divided into control and treatment groups, and each group had 52 cases. The patients in the control group were po administered with Glyburide Tablets 0.5 h before meals, 2.5 mg/time, three times daily. The patients in the treatment group were po administered with Shenqi Jiangtang Capsules at the basis of the control group, 3 capsules/time, three times daily. The patients in two groups were treated for 8 weeks. The level of fasting plasma glucose (FPG), the 2-hour postprandial blood glucose (2 h PG), HbA1C, blood glucose target rate, blood glucose standard time, and score of TCM syndrome in two groups before and after treatment were determined. Efficacy and the incidence of hypoglycemia between two groups before and after treatment were also compared. Results After treatment, FPG, 2hPG, and HbA1C of two groups were significantly decreased, and the difference was statistically significant in the same group before and after treatment (P< 0.05, 0.01). After treatment, FPG, 2 h PG, and HbA1C in treatment group were lower than those in the control group, and there were differences between two groups (P< 0.05, 0.01). Blood glucose standard time, changes of blood glucose, and hypoglycemia incidence in the treatment group were lower than those in the control group, and there were differences between two groups (P< 0.05). After treatment, the score of TCM syndrome in two groups were significantly reduced, and the difference was statistically significant in the same group before and after treatment (P< 0.05, 0.01). After treatment, the indicators in the treatment group were lower than those in the control group, and there were differences between two groups (P< 0.05). The efficacies in the treatment and control groups were 94.23% and 84.62%, respectively, with differences between the two groups (P< 0.05). Patients in two groups did not appear serious adverse reactions. Conclusion Shenqi Jiangtang Capsules combined with Glyburide Tablets has the good clinical effect in treatment of controlling blood glucose, shortening blood glucose target rate, reaching blood glucose standard time, and lowering incidence of hypoglycemia on the patients with type 2 diabetes mellitus than Glyburide Tablets alone. It exactly improves the clinical curative effect and helps reduce long-term complications, which is worth clinical application.